[1]Nguyen Xuan Huynh(越南),梁 硕,孟 毅,等.益气活血清热解毒方治疗动脉粥样硬化临床研究[J].陕西中医,2023,(6):746-750.[doi:DOI:10.3969/j.issn.1000-7369.2023.06.014]
　Nguyen Xuan Huynh,LIANG Shuo,MENG Yi,et al.Clinical study of Yiqi Huoxue Qingre Jiedu recipe in the treatment of atherosclerosis[J].,2023,(6):746-750.[doi:DOI:10.3969/j.issn.1000-7369.2023.06.014]
点击复制

益气活血清热解毒方治疗动脉粥样硬化临床研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2023年6期
页码:
746-750
栏目:
临床研究
出版日期:
2023-06-05

文章信息/Info

Title:
Clinical study of Yiqi Huoxue Qingre Jiedu recipe in the treatment of atherosclerosis
作者:
Nguyen Xuan Huynh1(越南); 梁 硕2; 孟 毅3; 刘志勇3
(1.河南中医药大学,河南 郑州 450003; 2.河南中医药大学第二临床医学院,河南 郑州 450002; 3.河南省中医院,河南 郑州 450002)
Author(s):
Nguyen Xuan Huynh; LIANG Shuo; MENG Yi;  LIU Zhiyong
(Henan University of Traditional Chinese Medicine,Zhengzhou 450003,China)
关键词:
动脉粥样硬化;  益气活血清热解毒方;  炎症;  血管内膜;  血流动力学;  血液流变学
Keywords:
Atherosclerosis;  Yiqi Huoxue Qingre Jiedu recipe;  Inflammation;  Intima vascularis;  Hemodynamics;  Hemorheology
分类号:
R 541.4
DOI:
DOI:10.3969/j.issn.1000-7369.2023.06.014
文献标志码:
A
摘要:
目的:观察益气活血清热解毒方治疗动脉粥样硬化患者临床疗效。方法:选择动脉粥样硬化患者122例,根据随机数字表法分组,61例为基础治疗组,给予常规西医治疗; 61例患者为中医方剂治疗组,在基础治疗同时给予益气活血清热解毒方治疗。检测两组患者治疗前后一氧化氮(NO)、可溶性细胞间黏附分子-1(sICAM-1)、血管内皮生长因子(VEGF)、血管性血友病因子(vWF)、氧化低密度脂蛋白(ox-LDL)、白细胞介素-37(IL-37)、二肽基肽酶4(DPP4)、脂蛋白相关磷脂酶A2(Lp-PLA2)水平,检测患者血浆黏度、纤维蛋白原、细胞沉降率,检测颈动脉收缩期峰值流速(PSV)、血管搏动指数(PI)、血管阻力指数(RI)、舒张末期流速(EDV),观察患者中医证候评分,比较两组临床疗效。结果:中医方剂治疗组患者ox-LDL、DPP4、Lp-PLA2水平较基础治疗组明显低(P<0.05),中医方剂治疗组IL-37水平较基础治疗组明显高(P<0.05)。中医方剂治疗组患者sICAM-1、VEGF、vWF含量较基础治疗组低,差异具有统计学意义(P<0.05)。中医方剂治疗组患者NO含量较基础治疗组明显升高(P<0.05),血浆黏度、纤维蛋白原、细胞沉降率及患者PI、RI较基础治疗组明显低(P<0.05),两组PSV、EDV比较,中医方剂治疗组明显高于基础治疗组(P<0.05)。患者尿黄赤、发热、口臭、便秘、口干、口苦评分比较,中医方剂治疗组较西医治疗组明显降低,差异具有统计学意义(P<0.05)。中医方剂治疗组总有效率(98.36%)明显高于基础治疗组(85.25%),差异具有统计学意义(P<0.05)。结论:益气活血清热解毒方治疗动脉粥样硬化患者,可抑制机体炎症,减少血管内皮功能损伤,保护血管内膜,改善患者血液流变学及血流动力学指标,提升患者临床疗效。
Abstract:
Objective:To investigate the protective effects of Yiqi Huoxue Qingre Jiedu recipe on atherosclerosis.Methods:A total of 122 patients with atherosclerosis were grouped according to random number table method.61 patients were in the basic treatment group and received conventional western medicine treatment,while 61 patients were in the traditional Chinese medicine treatment group.In the basic treatment group,patients were treated with Yiqi Huoxue Qingre Jiedu prescription.Nitric oxide(NO),soluble intercellular adhesion molecule-1(sICAM-1),vascular endothelial growth factor(VEGF),von willepian factor(vWF)and oxidization low density lipoprotein were detected in 2 groups before and after treatment(ox-LDL),interleukin-37(IL-37),dipeptidyl peptidase 4(DPP4),lipoprotein-associated phospholipase A2(Lp-PLA2)levels was detected before and after treatment in two groups.Plasma viscosity,fibrinogen,cell sedimentation rate,carotid systolic peak velocity(PSV),vascular pulsation index(PI),vascular resistance index(RI),and end-diastolic velocity(EDV)were detected.TCM syndrome scores were given to patients,and clinical efficacy of basic treatment group and TCM prescription treatment group were compared.Results:The levels of ox-LDL,DPP4 and Lp-PLA2 in TCM prescription treatment group were significantly lower than those in basic treatment group(P<0.05),and the level of IL-37 in TCM prescription treatment group was significantly higher than that in basic treatment group(P<0.05).The contents of sICAM-1,VEGF and vWF in TCM prescription treatment group were significantly lower than those in basic treatment group(P<0.05).The content of NO in TCM prescription treatment group was higher than that in basic treatment group(P<0.05),the plasma viscosity,fibrinogen and cell sedimentation rate,PI and RI in TCM prescription treatment group were significantly lower than those in basic treatment group(P<0.05),PSV and EDV in TCM prescription treatment group were significantly higher than those in basic treatment group(P<0.05).The scores of urinary yellow,fever,bad breath,constipation,dry mouth and bitter mouth in TCM treatment group were significantly lower than those in western treatment group(P<0.05).The total effective rate of TCM prescription treatment group was 98.36%,and that of basic treatment group was 85.25%.The total effective rate of TCM prescription treatment group was higher than that of basic treatment group(P<0.05).Conclusion:Yiqi Huoxue Qingre Jiedu recipe can inhibit inflammation,reduce vascular endothelial function damage,protect vascular intima,improve hemorheology and hemodynamics indexes of patients,and enhance clinical efficacy of patients with atherosclerosis.

参考文献/References:

[1] 刘子歌,刘 洋,宋国瑞,等.泡沫细胞在动脉粥样硬化形成过程中的作用研究进展[J].陕西医学杂志,2020,49(10):1363-1366.
[2] 崔国艳,高 虹,李丽晶,等.冠状动脉粥样硬化患者血清CPP、KS的表达水平与冠脉狭窄程度的相关性及诊断价值[J].西部医学,2022,34(3):443-447.
[3] 蔡 婉,周 华,葛 文,等.清脂化瘀颗粒调控Keap-1/Nrf2/ARE介导的氧化损伤抗动脉粥样硬化的作用及机制研究[J].陕西中医,2022,43(2):166-169,176.
[4] 陈宏丹,李 慧,柳 雯,等.阿利西尤单抗联合匹伐他汀治疗老年动脉粥样硬化患者的疗效[J].心血管康复医学杂志,2022,31(6):693-698.
[5] 中国中西医结合学会心血管病专业委员会血脂与动脉粥样硬化学组.动脉粥样硬化中西医结合诊疗专家共识[J].中国全科医学,2017,20(5):507-511.
[6] 中国中西医结合学会活血化瘀专业委员会.血瘀证中西医结合诊疗共识[J].中国中西医结合杂志,2011,31(6):839-844.
[7] 国家食品药品监督管理总局.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:383-385.
[8] Orekhov AN,Poznyak AV,Sobenin IA,et al.Mitochondrion as a selective target for the treatment of atherosclerosis:Role of mitochondrial DNA mutations and defective mitophagy in the pathogenesis of atherosclerosis and chronic inflammation[J].Curr Neuropharmacol,2020,18(11):1064-1075.
[9] 贺东红,黄亮星.大动脉粥样硬化性前循环脑梗死患者临床特征及预后影响因素分析[J].陕西医学杂志,2020,49(7):800-803.
[10] Anto L,Blesso CN.Interplay between diet,the gut microbiome,and atherosclerosis:Role of dysbiosis and microbial metabolites on inflammation and disordered lipid metabolism[J].The Journal of Nutritional Biochemistry,2022,105(2):108991.
[11] Shoeibi S,Mahdipour E,Mohammadi S,et al.Treatment of atherosclerosis through transplantation of endothelial progenitor cells overexpressing dimethylarginine dimethylaminohydrolase(DDAH)in rabbits[J].International Journal of Cardiology,2021,12(1):331189-331198.
[12] 李丹丹,梅 俊,周庆兵,等.固有免疫介导的炎症反应在动脉粥样硬化发病机制中的研究进展[J].中国动脉硬化杂志,2022,30(1):71-76.
[13] Mitu O,Cirneala IA,Lupsan AI,et al.The effect of vitamin supplementation on subclinical atherosclerosis in patients without manifest cardiovascular diseases:Never-ending hope or underestimated effect?[J].Molecules,2020,25(7):1717.
[14] 中国医师协会中西医结合分会心血管专业委员会,中华中医药学会心血管病分会.动脉粥样硬化中西医防治专家共识(2021年)[J].中国中西医结合杂志,2022,42(3):287-293.
[15] 冯 君,刘建和,冉俊宁,等.从痰、瘀、虚探讨动脉粥样硬化的中西医病机[J].陕西中医,2020,41(2):217-219.
[16] 马艳春,胡建辉,吴文轩,等.黄芪化学成分及药理作用研究进展[J].中医药学报,2022,50(4):92-95.
[17] 张瑞华,张静文,刘 玲,等.黄芪及其有效组分药理作用与临床应用现状[J].陕西中医,2021,42(8):1138-1141,1146.
[18] 李 芊,吴效科.川芎化学成分及药理作用研究新进展[J].化学工程师,2020,34(1):62-64.
[19] 王有清,张富娥,郭虎林,等.动脉粥样硬化型ACI患者血清Lp-PLA2、MCP-1、VE-cadherin、PTX3变化及与IMT的关系[J].脑与神经疾病杂志,2020,28(7):402-407.
[20] 周梦阳.冠心病患者血清DPP4水平与冠脉病变的关系[D]. 石家庄:河北医科大学,2015.
[21] 曹程浩,董晓瑞,黄 斌.丹参饮合二陈汤加减对颈动脉粥样硬化血管内膜损伤的保护作用[J].中国实验方剂学杂志,2021,27(7):86-91.
[22] 朱静和,钱 雷,蒋 凤,等.白细胞介素-37对动脉粥样硬化患者单核巨噬细胞脂蛋白相关磷脂酶A2的抑制作用[J].中华老年心脑血管病杂志,2020,22(8):873-875.
[23] 瞿 凯,邱菊辉,王贵学.血管内皮细胞屏障功能的血流动力学调控及其与动脉粥样硬化的关系[J].中国动脉硬化杂志,2020,28(1):1-6.
[24] 樊 蓉,任卫东.超声评估冠状动脉粥样硬化性心脏病患者二尖瓣环移位参数及其与血清Hcy、vWF及CysC水平的相关性研究[J].中国现代医学杂志,2020,30(13):23-26.
[25] 刘演龙,光雪峰,尹小龙,等.miR-125a-3p对动脉粥样硬化斑块及M1/M2巨噬细胞、MMP-9和VEGF的影响[J].昆明医科大学学报,2022,43(9):1-6.

相似文献/References:

[1]王清亮,陆文杰,陈咸川.益气活血化痰通络方对颈动脉粥样硬化患者T细胞亚群影响的研究[J].陕西中医,2019,(3):307.
　WANG Qingliang,LU Wenjie,CHEN Xianchuan..Effect of Yiqi Huoxue Huatan Tongluo formula on Tcells subset in patients with carotid atherosclerosis[J].,2019,(6):307.
[2]陈 静,陈 炜,伍 媛,等.小续命汤及其组分治疗急性脑梗死研究进展*[J].陕西中医,2019,(12):1818.
[3]冯 君,刘建和,冉俊宁,等.从痰、瘀、虚探讨动脉粥样硬化的中西医病机*[J].陕西中医,2020,(2):217.
　FENG Jun,LIU Jianhe,RAN Junning,et al.Discussion on the pathogenesis of atherosclerosis from phlegm,blood stasis and asthenia[J].,2020,(6):217.
[4]秦 魏,邢 露,杨智慧,等.丹参活性成分在抗动脉粥样硬化中的作用与机制研究进展[J].陕西中医,2021,(7):977.[doi:DOI:10.3969/j.issn.1000-7369.2020.07.044]
[5]蔡 婉,周 华,葛 文,等.清脂化瘀颗粒调控Keap-1/Nrf2/ARE介导的氧化损伤抗动脉粥样硬化的作用及机制研究[J].陕西中医,2022,(2):166.[doi:DOI:10.3969/j.issn.1000-7369.2022.02.006]
　CAI Wan,ZHOU Hua,GE Wen,et al.Effect and mechanism of Qingzhi Huayu granule on regulating Keap-1/Nrf2/ARE mediated oxidative damage and anti atherosclerosis[J].,2022,(6):166.[doi:DOI:10.3969/j.issn.1000-7369.2022.02.006]
[6]陈抒鹏,王思梦,唐娜娜,等.基于浊邪与铁死亡相关性探析动脉粥样硬化之病机[J].陕西中医,2022,(11):1589.[doi:DOI:10.3969/j.issn.1000-7369.2022.11.023]
　CHEN Shupeng,WANG Simeng,TANG Nana,et al.Exploring the pathogenesis of atherosclerosis based on the correlation between turbid pathogens and ferroptosis[J].,2022,(6):1589.[doi:DOI:10.3969/j.issn.1000-7369.2022.11.023]
[7]黄昌锐,李汶珊,袁 惠,等.护心康片对动脉粥样硬化小鼠自噬干预机制[J].陕西中医,2023,(7):854.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.006]
　HUANG Changrui,LI Wenshan,YUAN Hui,et al.Intervention mechanism of cardiac protection tablets on autophagy in atherosclerotic mice[J].,2023,(6):854.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.006]
[8]陈 姣,罗丹梅,孙承霞,等.扶正化浊法治疗动脉粥样硬化研究进展[J].陕西中医,2023,(11):1653.[doi:DOI:10.3969/j.issn.1000-7369.2023.11.039]
　CHEN Jiao,LUO Danmei,SUN Chengxia,et al.Research progress of atherosclerosis based on Fuzheng Huazhuo treatment[J].,2023,(6):1653.[doi:DOI:10.3969/j.issn.1000-7369.2023.11.039]

备注/Memo

备注/Memo:
基金项目:河南省中医药科学研究专项课题(20-21ZY1024)
更新日期/Last Update: 2023-06-09